Paper Details

  1. Home
  2. Paper Details

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.

Author: ChauhanBhupendrasinh F, DucharmeFrancine M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review found that in adults with asthma inadequately controlled by inhaled corticosteroids (ICS), adding a long-acting beta2-agonist (LABA) to ICS is modestly superior to adding an anti-leukotriene (LTRA) in reducing oral corticosteroid-treated exacerbations. The absolute reduction in exacerbations was two percentage points. LABA was also superior to LTRA in improving lung function and reducing rescue medication use. However, there was a slightly increased risk of serious adverse events (SAE) with LABA compared to LTRA, with an absolute increase of one percentage point.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) and anti-leukotrienes (LTRA) are two treatment options that could be considered as add-on therapy to ICS. OBJECTIV...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514761/

データ提供：米国国立医学図書館（NLM）

Inhaled Corticosteroids: LABA vs. Anti-Leukotrienes for Chronic Asthma

Managing chronic asthma is like traversing a desert landscape, often requiring a combination of approaches to effectively control symptoms. This review examines the relative effectiveness of two add-on therapies, long-acting beta2-agonists (LABA) and anti-leukotrienes (LTRA), for asthma patients who remain symptomatic despite taking inhaled corticosteroids (ICS). The review is a comprehensive analysis of randomized controlled trials, providing a robust assessment of these treatment options.

The authors conclude that adding LABA to ICS is modestly superior to adding LTRA in reducing asthma exacerbations, improving lung function, and enhancing overall asthma control. However, they also highlight a slightly increased risk of serious adverse events with LABA compared to LTRA, emphasizing the need for careful consideration of the potential risks and benefits of each treatment option.

LABA: A Modest Advantage for Asthma Control

This review suggests that LABA may be a slightly more effective option than LTRA for managing asthma in patients who remain symptomatic despite taking ICS. However, the authors emphasize that the difference in effectiveness is modest and the potential risks of each treatment option should be carefully considered.

The Importance of Individualized Asthma Management

Asthma is a complex condition, and each patient's needs are unique. This review emphasizes the importance of working with your healthcare provider to develop an individualized asthma management plan that considers your specific symptoms, medical history, and potential risks and benefits of different treatment options.

Dr.Camel's Conclusion

The desert of asthma management can be challenging, but this review offers valuable insights into the relative effectiveness of LABA and LTRA as add-on therapies for patients who remain symptomatic despite taking ICS. The findings suggest that LABA may offer a modest advantage in improving asthma control, but the potential risks of each treatment option should be carefully considered.

Date :
  1. Date Completed 2014-07-01
  2. Date Revised 2023-09-24
Further Info :

Pubmed ID

24459050

DOI: Digital Object Identifier

PMC10514761

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.